menu search

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Tristate capital bank named again to monitor 101+ list for fast-growing equipment finance

PITTSBURGH--(BUSINESS WIRE)--For the second year in a row, TriState Capital Bank was named to the Monitor 101+ list for the bank's fast-growing Equipm...

October 8, 2021, 5:11 pm

Tristate capital bank named again to monitor 101+ list for fast-growing equipment finance

PITTSBURGH--(BUSINESS WIRE)--For the second year in a row, TriState Capital Bank was named to the Monitor 101+ list for the bank's fast-growing Equipm...

October 8, 2021, 5:11 pm

Tristate capital bank named again to monitor 101+ list for fast-growing equipment finance

PITTSBURGH--(BUSINESS WIRE)--For the second year in a row, TriState Capital Bank was named to the Monitor 101+ list for the bank's fast-growing Equipm...

October 8, 2021, 5:11 pm

Check point: infinity could justify a spike from $101-$119 to $245

Check Point Software Technologies Ltd. offers three different options to secure the network, the cloud, and the client's users....

October 8, 2021, 12:00 pm

Check point: infinity could justify a spike from $101-$119 to $245

Check Point Software Technologies Ltd. offers three different options to secure the network, the cloud, and the client's users....

October 8, 2021, 12:00 pm

Check point: infinity could justify a spike from $101-$119 to $245

Check Point Software Technologies Ltd. offers three different options to secure the network, the cloud, and the client's users....

October 8, 2021, 12:00 pm

Nkarta expects initial data from car nk cell therapy in blood cancer in 2022

Nkarta Inc (NASDAQ: NKTX) has updated guidance on initial data readout of Phase 1 trial of NKX101 in...

October 8, 2021, 8:11 am

Nkarta expects initial data from car nk cell therapy in blood cancer in 2022

Nkarta Inc (NASDAQ: NKTX) has updated guidance on initial data readout of Phase 1 trial of NKX101 in...

October 8, 2021, 8:11 am


Search within

Pages Search Results: